Search

Your search keyword '"Liu, Qifa"' showing total 25 results
Start Over Author "Liu, Qifa" Publisher wiley
25 results on '"Liu, Qifa"'

1. An integrated classification of tumor suppressor IKZF1 inactivation and oncogenic activation in Philadelphia chromosome‐like acute lymphoblastic leukemia

Author

Huang, Zicong, primary, Zhang, Ling, additional, Gong, Xiaoyuan, additional, Li, Jia, additional, Deng, Shiyu, additional, Cai, Zihong, additional, Tang, Bingqing, additional, Huang, Kangyu, additional, Li, Xin, additional, Zhao, Weihua, additional, Xu, Yang, additional, Xuan, Li, additional, Liu, Qifa, additional, Wang, Ying, additional, Chen, Suning, additional, and Zhou, Hongsheng, additional

Published
2024
Full Text
View/download PDF

2. Impact of measurable residual disease in combination with CD19 on postremission therapy choices for adult t(8;21) acute myeloid leukemia in first complete remission

Author

Jia, Xi, primary, Liao, Naying, additional, Yu, Sijian, additional, Li, Huan, additional, Liu, Hui, additional, Zhang, Haiyan, additional, Xu, Jun, additional, Yao, Yunqian, additional, He, Han, additional, Yu, Guopan, additional, Liu, Qifa, additional, Zhang, Yu, additional, and Shi, Pengcheng, additional

Published
2024
Full Text
View/download PDF

3. Adoptive therapy with cytomegalovirus‐specific cytotoxic T lymphocytes for refractory cytomegalovirus DNAemia and disease after allogeneic haematopoietic stem cell transplantation

Author

Jiang, Zhonghui, primary, Fan, Zhiping, additional, Zhang, Tian, additional, Lin, Ren, additional, Xu, Hui, additional, Xu, Na, additional, Huang, Fen, additional, Chi, Peiru, additional, Ou, Xueying, additional, Wang, Zhixiang, additional, Liu, Hui, additional, Zhao, Ke, additional, Jiang, Ling, additional, Yu, Sijian, additional, Sun, Jing, additional, Liu, Qifa, additional, and Xuan, Li, additional

Published
2024
Full Text
View/download PDF

4. PASS‐ALL study of paediatric‐inspired versus adult chemotherapy regimens on survival of high‐risk Philadelphia‐negative B‐cell acute lymphoblastic leukaemia with allogeneic haematopoietic stem cell transplantation

Author

Wang, Zhixiang, primary, Fan, Zhiping, additional, Wu, Zhengwei, additional, Xuan, Li, additional, Li, Xin, additional, Tang, Bingqing, additional, Liu, Yiqian, additional, He, Jiabao, additional, Huang, Kangyu, additional, Zhou, Xuan, additional, Gao, Ya, additional, Wang, Qiang, additional, Li, Xiaofang, additional, Lin, Ren, additional, Xu, Na, additional, Huang, Feng, additional, Wang, Shunqing, additional, Liang, Xingquan, additional, Zhang, Jingdong, additional, Liu, Xiaoli, additional, Sun, Jing, additional, Liu, Qifa, additional, and Zhou, Hongsheng, additional

Published
2023
Full Text
View/download PDF

5. Sorafenib plus triplet therapy with venetoclax, azacitidine and homoharringtonine for refractory/relapsed acute myeloid leukemia with FLT3‐ITD: A multicenter phase 2 study

Author

Yu, Sijian, primary, Zhang, Yu, additional, Yu, Guopan, additional, Wang, Yu, additional, Shao, Ruoyang, additional, Du, Xin, additional, Xu, Na, additional, Lin, Dongjun, additional, Zhao, Weihua, additional, Zhang, Xiong, additional, Xiao, Jie, additional, Sun, Zhiqiang, additional, Deng, Lan, additional, Liang, Xinquan, additional, Zhang, Hongyu, additional, Guo, Ziwen, additional, Dai, Min, additional, Shi, Pengcheng, additional, Huang, Fen, additional, Fan, Zhiping, additional, Liu, Qiong, additional, Lin, Ren, additional, Jiang, Xuejie, additional, Xuan, Li, additional, Liu, Qifa, additional, and Jin, Hua, additional

Published
2023
Full Text
View/download PDF

6. Idarubicin plus BuCy versus BuCy conditioning regimens for intermediate‐risk acute myeloid leukemia in first complete remission undergoing auto‐HSCT: An open‐label, multicenter, randomized phase 3 trial

Author

Liu, Hui, primary, Huang, Fen, additional, Zhang, Yu, additional, Wu, Meiqing, additional, Xu, Na, additional, Fan, Zhiping, additional, Sun, Zhiqiang, additional, Li, Xudong, additional, Lin, Dongjun, additional, Xiong, Yiying, additional, Liu, Xiaodan, additional, Lin, Ren, additional, Shi, Pengcheng, additional, Xu, Jun, additional, Wang, Zhixiang, additional, Li, Xiaofang, additional, Sun, Jing, additional, Liu, Qifa, additional, and Xuan, Li, additional

Published
2023
Full Text
View/download PDF

7. Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia

Author

Weng, Guangyang, primary, Zhang, Yu, additional, Yu, Guopan, additional, Luo, Tingyue, additional, Yu, Sijian, additional, Xu, Na, additional, Sun, Zhiqiang, additional, Lin, Dongjun, additional, Deng, Lan, additional, Liang, Xinquan, additional, Xiao, Jie, additional, Zhang, Hongyu, additional, Guo, Ziwen, additional, Shao, Ruoyang, additional, Du, Xin, additional, Jin, Hua, additional, and Liu, Qifa, additional

Published
2022
Full Text
View/download PDF

8. De‐escalation or discontinuation of tyrosine kinase inhibitor in patients with chronic myeloid leukemia: A multicentral, open‐label, prospective trial in China

Author

Luo, Jie, primary, Du, Xin, additional, Lou, Jin, additional, Wu, Jianwei, additional, Ma, Liping, additional, Huang, Jixian, additional, Wang, Liangtuo, additional, Tu, Chuanqing, additional, Liu, Zelin, additional, Chen, Liya, additional, Tan, Yaxian, additional, Luo, Dongmei, additional, Liang, Hanyin, additional, Yin, Changxin, additional, Cao, Rui, additional, Zhou, Xuan, additional, Liu, Qifa, additional, Liu, Xiaoli, additional, and Xu, Na, additional

Published
2022
Full Text
View/download PDF

9. A phase 2 study of sorafenib combined with conventional therapies in refractory central nervous system leukemia

Author

Chen, Xiaoxia, primary, Huang, Junwei, additional, Xu, Na, additional, Fan, Zhiping, additional, Nie, Danian, additional, Huang, Fen, additional, Sun, Qixin, additional, Zhang, Xinyou, additional, Liang, Xinquan, additional, Shi, Pengcheng, additional, Wang, Zhixiang, additional, Liu, Hui, additional, Xu, Jun, additional, Dai, Min, additional, Yu, Guopan, additional, Zhang, Yu, additional, Sun, Jing, additional, Liu, Qifa, additional, and Xuan, Li, additional

Published
2022
Full Text
View/download PDF

10. Cidofovir, a choice for salvage treatment of cytomegalovirus infection in patients with haploidentical hematopoietic stem cell transplantation

Author

Yin, Zhao, primary, Sun, Jing, additional, Yang, Ying, additional, Xu, Na, additional, Jiang, Ling, additional, Fan, Zhiping, additional, Huang, Fen, additional, Shi, Pengcheng, additional, Wang, Zhixiang, additional, Xuan, Li, additional, Xu, Jun, additional, Liu, Qifa, additional, and Yu, Guopan, additional

Published
2022
Full Text
View/download PDF

11. Requirements for human haematopoietic stem/progenitor cells

Author

Nan, Xue, primary, Zhang, Bowen, additional, Hao, Jie, additional, Yue, Wen, additional, Fu, Boqiang, additional, Qu, Mingyi, additional, Zhang, Yu, additional, Wang, Haiyang, additional, Fang, Fang, additional, Wei, Jun, additional, Li, Qiyuan, additional, Hu, Shijun, additional, Yu, Junying, additional, Gao, Yingdai, additional, Liu, Qifa, additional, Cao, Jiani, additional, Wang, Lei, additional, Peng, Yaojin, additional, Zhu, Huanxin, additional, Liang, Lingmin, additional, Ma, Aijin, additional, Zhou, Jiaxi, additional, Zhao, Tongbiao, additional, and Pei, Xuetao, additional

Published
2021
Full Text
View/download PDF

12. Upfront transplantation may have better outcomes than pretransplant cytoreductive therapy for treating patients with MDS‐EB ‐1 or MDS‐EB ‐2

Author

Chen, Yili, primary, Huang, Fen, additional, Xuan, Li, additional, Zhang, Yu, additional, Fan, Zhiping, additional, Xu, Na, additional, Zhao, Ke, additional, Xu, Jun, additional, Liu, Hui, additional, Shi, Pengcheng, additional, Wang, Zhixiang, additional, Sun, Jing, additional, Zheng, Weiyang, additional, Dai, Min, additional, and Liu, Qifa, additional

Published
2021
Full Text
View/download PDF

13. Haploidentical related donor vs matched sibling donor allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome aged over 50 years: A single‐center retrospective study

Author

Huang, Jiafu, primary, Huang, Fen, additional, Fan, Zhiping, additional, Xu, Na, additional, Xuan, Li, additional, Liu, Hui, additional, Shi, Pengcheng, additional, Jiang, Ling, additional, Zhang, Yu, additional, Sun, Jing, additional, and Liu, Qifa, additional

Published
2020
Full Text
View/download PDF

15. Effect of sorafenib on the outcomes of patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation

Author

Xuan, Li, primary, Wang, Yu, additional, Huang, Fen, additional, Jiang, Erlie, additional, Deng, Lan, additional, Wu, Bingyi, additional, Fan, Zhiping, additional, Liang, Xinquan, additional, Xu, Na, additional, Ye, Jieyu, additional, Lin, Ren, additional, Yin, Changxin, additional, Zhang, Yuanyuan, additional, Sun, Jing, additional, Han, Mingzhe, additional, Huang, Xiaojun, additional, and Liu, Qifa, additional

Published
2018
Full Text
View/download PDF

16. Application of autologous hematopoietic stem cell transplantation for pemphigus

Author

Wang, Menglei, primary, Cao, Can, additional, Sun, Jing, additional, Peng, Xuebiao, additional, Liu, Qifa, additional, Huang, Liang, additional, Chai, Yanyan, additional, Lai, Kuan, additional, Chen, Pingjiao, additional, Liu, Qingxiu, additional, Li, Qian, additional, Peng, Yusheng, additional, Xiong, Hao, additional, Zhang, Jing, additional, Chen, Minghua, additional, and Zeng, Kang, additional

Published
2017
Full Text
View/download PDF

17. Alteration of Naïve and Memory B-Cell Subset in Chronic Graft-Versus-Host Disease Patients After Treatment With Mesenchymal Stromal Cells

Author

Peng, Yanwen, primary, Chen, Xiaoyong, additional, Liu, Qifa, additional, Xu, Dijing, additional, Zheng, Haiqing, additional, Liu, Longshan, additional, Liu, Qiuli, additional, Liu, Muyun, additional, Fan, Zhiping, additional, Sun, Jing, additional, Li, Xiaobo, additional, Zou, Ruifeng, additional, and Xiang, Andy Peng, additional

Published
2014
Full Text
View/download PDF

19. Molecular monitoring and stepwise preemptive therapy for Epstein–Barr virus viremia after allogeneic stem cell transplantation

Author

Liu, Qifa, primary, Xuan, Li, additional, Liu, Hui, additional, Huang, Fen, additional, Zhou, Hongsheng, additional, Fan, Zhiping, additional, Zhao, Ke, additional, Wu, Meiqing, additional, Xu, Lanping, additional, Zhai, Xiao, additional, Zhang, Fuhua, additional, Liu, Can, additional, Sun, Jing, additional, and Huang, Xiaojun, additional

Published
2013
Full Text
View/download PDF

22. Early T-Cell Precursor Leukemia Has a Higher Risk of Induction-Related Infection among T-Cell Acute Lymphoblastic Leukemia in Adult.

Author

Huang K, Dai M, Li Q, Liu N, Lin D, Wang Q, Zhou X, Wang Z, Gao Y, Jin H, Liu X, Liu Q, and Zhou H

Subjects
Adolescent, Adult, Antineoplastic Agents pharmacology, Female, Humans, Immunophenotyping, Infections etiology, Male, Precursor Cell Lymphoblastic Leukemia-Lymphoma diagnosis, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma diagnosis, Prevalence, Prognosis, Remission Induction, Retrospective Studies, Risk, Risk Factors, Young Adult, Induction Chemotherapy adverse effects, Infections complications, Precursor Cell Lymphoblastic Leukemia-Lymphoma complications, Precursor Cells, T-Lymphoid cytology, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma complications
Abstract

Background: Infections are an important cause of morbidity and mortality for acute lymphoblastic leukemia (ALL). However, the reports regarding risk factors of induction-related infection are roughly unknown/limited in adult T-ALL during induction chemotherapy., Methods: We performed a retrospective cohort study for the prevalence and risk predictors of induction-related infection among consecutive T-ALL patients ( N = 97) enrolled in a PDT-ALL-LBL clinical trial. Of 97 patients with T-ALL enrolled in the trial, 46 were early T-cell precursor (ETP) ALL and 51 were non-ETP ALL., Results: When compared with non-ETP, ETP ALL subtype was characterized with lower neutrophil count (1.35 × 10 9 /L vs. 8.7 × 10 9 /L, P < 0.001) and lower myeloid percentage in the bone marrow (13.35% vs. 35.31%, P = 0.007). Additionally, ETP ALL had longer neutropenia before diagnosis ( P < 0.001), as well as during induction chemotherapy ( P < 0.001). Notably, the ETP cohort experienced higher cumulative incidence of clinically documented infections (CDI; 33.33%, P = 0.001), microbiologically documented infections (MDI; 45.24%, P = 0.006), resistant infection (11.9%, P = 0.013), and mixed infection (21.43%, P = 0.003), respectively, than those of the non-ETP cohort. Furthermore, multivariable analysis revealed that T-ALL mixed infection was more likely related to chemotherapy response (OR, 0.025; 95% CI 0.127-0.64; P = 0.012) and identified myeloid percentage as a predictor associated with ETP-ALL mixed infection (OR, 0.915; 95% CI 0.843-0.993; P = 0.033), with ROC-defined cut-off value of 2.24% in ETP cohorts., Conclusions: Our data for the first time demonstrated that ETP-ALL characterized with impaired myelopoiesis were more susceptible to induction-related infection among T-ALL populations., Competing Interests: The authors declare that they have no conflicts of interest., (Copyright © 2020 Kangyu Huang et al.)

Published
2020
Full Text
View/download PDF

23. Clinical Characteristics of Patients with Different N-Terminal Probrain Natriuretic Peptide Levels after Hematopoietic Stem Cell Transplantation.

Author

Se Z, Zhou H, Li H, Sun J, Zhan Q, Zeng Q, Liu Q, and Xu D

Subjects
Adult, Antilymphocyte Serum therapeutic use, Cyclosporine therapeutic use, Female, Graft vs Host Disease prevention & control, Heart Failure blood, Hematopoietic Stem Cell Transplantation methods, Humans, Male, Methotrexate therapeutic use, Mycophenolic Acid therapeutic use, Retrospective Studies, Biomarkers blood, Heart Failure etiology, Hematologic Neoplasms therapy, Hematopoietic Stem Cell Transplantation adverse effects, Natriuretic Peptide, Brain blood, Peptide Fragments blood
Abstract

Heart failure (HF) is not uncommon among patients with hematologic malignancies (HM) undergoing hematopoietic stem cell transplantation (HSCT) and is associated with an increased mortality. Among HSCT patients without signs or symptoms of HF, groups with elevated and normal N-terminal probrain natriuretic peptide (NT-proBNP) levels have been poorly characterized in previous literature. Herein, we reviewed consecutive admissions for HM undergoing HSCT ( n = 301). Based on NT-proBNP levels and clinical signs or symptoms of HF at follow-up (one month after HSCT), patients were grouped into ENPH ( e levated N T-proBNP > 125 pg/mL, p resence of H F symptoms or signs), ENAH ( e levated N T-proBNP > 125 pg/mL, a bsence of H F symptoms or signs), and NN ( n ormal N T-proBNP < 125 pg/mL). ENPH, ENAH, and NN were observed in 22.9%, 54.5%, and 22.6% of patients, respectively. ENPH patients had a significantly higher baseline NT-proBNP level, followed by the ENAH and NN groups, respectively ( P < 0.001). Frequencies of HLA partially matched related donors, stem cell source (bone marrow+peripheral blood), and utilization of graft-versus-host disease prophylaxis regimens (ciclosporin+methotrexate+antithymocyte globulin±mycophenolate mofetil) were also the highest in the ENPH group, followed by ENAH and NN groups, respectively (all P < 0.05). Uric acid and hemoglobin levels, transplant type, and cyclophosphamide-based conditioning regimens utilized were similar between the ENAH and ENPH groups. We found that ENPH and ENAH are commonly observed in HM hospitalized for HSCT. Serum NT-proBNP levels may allow for earlier identification of HSCT patients at high risk of developing cardiac dysfunction., Competing Interests: The authors declare no conflict of interests., (Copyright © 2020 Zhen Se et al.)

Published
2020
Full Text
View/download PDF

24. Combination use of tolfenamic acid with curcumin improves anti-inflammatory activity and reduces toxicity in mice.

Author

Zhou W, Liu Q, Zang X, Hu M, Yue Y, Wang Y, Lv C, and Du Z

Subjects
Animals, Anti-Inflammatory Agents pharmacology, Mice, NF-kappa B, ortho-Aminobenzoates pharmacology, Curcumin pharmacology
Abstract

Long-term use of tolfenamic acid inevitably causes side effects, including gastric ulcer and hepatotoxicity. Curcumin is generally recognized to be anti-inflammatory, hepatoprotective, and gastroprotective. Herein, we investigated the combinational effects of tolfenamic acid and curcumin and possible mechanism in a TPA-induced inflammation mouse model. Combinational use of tolfenamic acid (100 mg/kg) and curcumin (100 mg/kg) by oral administration reduced dermal inflammation represented by ear edema and lymphocytic infiltration. Moreover, curcumin dispersed in polyvinyl pyrrolidone showed stronger synergistic effect. The beneficial effect of the coadministration was also reproduced in PKC/Akt/IKK/NF-κB signaling pathways. Notably, hepatoprotective and gastroprotective effect was exhibited by the reverse of body weight loss and NF-κB downregulation in the liver, and by increased Spleen Index of mice. These results suggested combination administration of tolfenamic acid with curcumin enhances anti-inflammatory efficacy and reduces hepatic/gastric toxicity, which indicates dietary uptake of curcumin may facilitate the function of tolfenamic acid. PRACTICAL APPLICATIONS: Curcumin, a representative polyphenolic compound, is one of the main constituents of dietary spice turmeric which has been widely consumed throughout the world, especially in Asia. The beneficial aspect of combination use of curcumin in enhancing anti-inflammatory effect and reducing hepatic/gastric toxicity of NSAID drug tolfenamic acid in mice has been explored. It might be anticipated as a potential naturally derived bioactive constituent in functional food and pharmaceutical applications., (© 2020 Wiley Periodicals, Inc.)

Published
2020
Full Text
View/download PDF

25. T cells immunology in the immunological diseases.

Author

Wu X, Przybylski GK, Yang Q, and Liu Q

Subjects
Gene Expression immunology, Humans, Immune System Diseases genetics, Immune System Diseases metabolism, Receptors, Antigen, T-Cell metabolism, T-Lymphocytes metabolism, Immune System Diseases immunology, Receptors, Antigen, T-Cell immunology, T-Lymphocytes immunology
Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results